The data from our preclinical melanoma model, along with the existing results in other preclinical models and clinical data indicating increased expression of the IFN-γ score in patients with advanced cutaneous melanoma (Bretz et al., 2019), together provided a strong rationale to test the combination of domatinostat with ICB in patients with melanoma. This evidence concerns the gene IFNG and cutaneous melanoma.